Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-011 in advanced solid tumors or lymphomas
NCT02582827Phase 1Withdrawn
- Sponsor
- NantBioScience
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-thiocolchicine dimer in solid tumor and lymphoma, sponsored by NantBioScience. Primary endpoint: Maximum Tolerated Dose at 1 year. Planned start Nov 2017; status: withdrawn.
02
Drugs
nab-thiocolchicine dimer
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02582827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582827.